Shi Yan

Haping Road 150
Harbin, 150081, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.

DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.

Journal: Cancer cell international

Published: February 16, 2024

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.

Journal: BMC cancer

Published: December 13, 2022

TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.

TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.

Journal: International journal of biological sciences

Published: January 21, 2022

Identification of Differentially Expressed Circular RNAs as miRNA Sponges in Lung Adenocarcinoma.

Identification of Differentially Expressed Circular RNAs as miRNA Sponges in Lung Adenocarcinoma.

Journal: Journal of oncology

Published: June 12, 2021

A feedback circuit comprising EHD1 and 14-3-3ζ sustains β-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.

A feedback circuit comprising EHD1 and 14-3-3ζ sustains β-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.

Journal: Cancer letters

Published: March 16, 2021

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy.

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy.

Journal: Frontiers in cell and developmental biology

Published: March 18, 2020

CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.

CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.

Journal: Aging

Published: December 30, 2019

Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.

Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.

Journal: Oncogene

Published: April 22, 2019

Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling.

Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 17, 2019

LRH1 as a promising prognostic biomarker and predictor of metastasis in patients with non-small cell lung cancer.

LRH1 as a promising prognostic biomarker and predictor of metastasis in patients with non-small cell lung cancer.

Journal: Thoracic cancer

Published: August 16, 2018

TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.

TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.

Journal: Cell communication and signaling : CCS

Published: April 13, 2018

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.

Journal: Cell death & disease

Published: December 06, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026